Baudax Bio, Inc. (BXRX)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Baudax Bio, Inc. (BXRX) is a publicly traded company in the Healthcare sector. Latest price: $0.02. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Baudax Bio, Inc.
Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.
Valuation
| P/E (TTM) | -0.00× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | -0.00× |
| PEG | 0.00× |
| P/FCF (TTM) | 0.00× |
| EV / EBITDA | -0.05× |
| EV / Sales | 1.47× |
| Earnings Yield | -813298.06% |
| Free Cash Flow Yield | 0.00% |
Fundamentals
| Enterprise Value | $1.86M |
|---|---|
| Revenue (TTM) | $1.27M |
| Net Income (TTM) | $0.00 |
| Free Cash Flow (TTM) | -$6.74M |
| Net Debt | $1.86M |
| Working Capital | -$15.11M |
| Gross Margin | -452.32% |
| Operating Margin | -2816.63% |
| Net Margin | -4633.18% |
| Return on Equity | 1067.45% |
| Return on Invested Capital | 613.30% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap